Report for Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Report for Q1 2026
Filed with SSE ·
6ix hasn’t read this filing yet.
Zhejiang East Asia Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang East Asia Pharmaceutical
- Announcement on Lifting Sales Restrictions and Listing in the 1st Lifting Period under the 2024 Restricted Stock Incentive Plan
- Announcement on Renewing Engagement of Financial and Internal Control Audit Institution for 2026
- Announcement on Conversion Result of Convertible Bonds and Share Changes
- Announcement on Completing the Repurchase and Cancellation of Some Restricted Stocks without Adjusting Conversion Price of Convertible Bonds
- Announcement on Obtaining Drug Registration Certificate for Saxagliptin and Metformin Hydrochloride Extended-Release Tablets
Later from Zhejiang East Asia Pharmaceutical
- Announcement on Obtaining Korea Pharmaceutical Raw Material Registration Certificate for Drug Substance Vonoprazan Fumarate by its Wholly-owned Subsidiary
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Completing Industrial and Commercial Change Registration of Business Scope and Obtaining Renewed Business License
- Announcement on 2026 Follow-up Rating Results of Convertible Corporate Bonds Issued to Non-specific Objects
- Announcement on SSE’s Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
Follow Zhejiang East Asia Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang East Asia Pharmaceutical